Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01149668 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
A Phase 1 study of Multiple Myeloma and Lymphoma, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 5
- Study locations
NCT01149668 is a Phase 1 study of Multiple Myeloma and Lymphoma that has completed, run by Pharmacyclics. The registered enrollment target is 7 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT01149668, a Phase 1 study of Multiple Myeloma and Lymphoma, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine the long-term (\> 6 months) safety of PCI 24781 PO in subjects with lymphoma.
Conditions Studied
Interventions
- DRUG PCI-24781
Study Locations (5)
Nebraska
- Nebraska Methodist Hospital - Omaha
- Univ. of Nebraska Medical Center - Omaha
Illinois
- Northwestern Univ. Med School - Chicago
Indiana
- Horizon Oncology Center - Lafayette
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01149668
The ClinicalTrials.gov registry entry for NCT01149668 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (99% lower). The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which PCI-24781 is the first listed.
NCT01149668 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Nebraska, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT01149668 about?
NCT01149668 is a clinical study titled "A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer". The purpose of this study is to determine the long-term (\> 6 months) safety of PCI 24781 PO in subjects with lymphoma.
What is the current status of trial NCT01149668?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2010-06. Estimated completion is 2013-04.
What conditions does trial NCT01149668 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Leukemia, Non-Hodgkin's Lymphoma, Hodgkin Disease.
What interventions are being tested in trial NCT01149668?
The interventions under investigation include: PCI-24781 (DRUG).
Who is sponsoring clinical trial NCT01149668?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01149668 being conducted?
This trial has 5 study locations across Illinois, Indiana, Nebraska, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.